Adinotec AG  

(Public, ETR:N1N)   Watch this stock  
Find more results for N1N
ETR data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.40 - 0.94
Open     -
Vol / Avg. 0.00/386.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.38
Shares 2.89M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -5163.10% -188.64%
Operating margin -5407.54% -187.59%
EBITD margin - -101.57%
Return on average assets -22.18% -14.16%
Return on average equity -348.78% -79.67%
Employees 13 -
CDP Score - -


Bunsenstrasse 5
+49-6155-824400 (Phone)
+49-6155-824495 (Fax)

Website links


Adinotec AG is a German company engaged in the development, production, and marketing of technology products, as well as in the patent and license business. Its activities are divided in two divisions: dietary foodstuffs for special medical purposes, medical devices and medicines division that operates through Adinotec AG�s dependent companies, Magnapharma GmbH and Neopharmacie GmbH, as well as industrial applications division, which is operational through the Company�s subsidiaries, Nanoplan GmbH and Poligate Ltd. The Company develops dietary foodstuff for the indications rheumatism and joint inflammations, as well as dietary foodstuff for abating the side effects of chemotherapy. In the medicine product field, the Company offers a gel against neurodermatitis and for wound healing. In addition, Adinotec AG offers soil stabilization products for road construction and road redevelopment. As of December 31, 2011, the Company had six wholly owned subsidiaries based in Germany and Malta.

Officers and directors

Thomas Milde Chairman of the Supervisory Board
Edmund Krix Chief Executive Officer, Member of the Management Board
Age: 54
Christian Eigen Vice Chairman of the Supervisory Board
Bruno Wuethrich Chief Operating Officer, Member of the Management Board
Marian A. von Korff Member of the Supervisory Board